

ASX Announcement

International Cardiometabolic Expert, Associate Professor Erin Howden Joins Race Oncology's Scientific Advisory Board

- Associate Professor Erin Howden is a world-leading expert on the serious negative effects of chemotherapy on cardiorespiratory fitness and patient quality of life
- Head of the Cardiometabolic Health and Exercise Physiology Lab and co-lead of the Physical Activity Program at the Baker Heart and Diabetes Institute
- Appointment enhances Race's cardioprotection-focused clinical program.

14 March 2024 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Associate Professor Erin Howden of the Baker Heart and Diabetes Institute (Melbourne, Australia) to Race's Scientific Advisory Board (SAB). Dr. Howden brings a wealth of experience to Race, having published more than 100 scientific publications on numerous topics, including the serious adverse effects that chemotherapy has on the cardiovascular fitness of cancer patients.

Recent work by Dr. Howden and her collaborators has identified that $VO_{2\text{ peak}}$ is a highly sensitive and clinically relevant measure of the significant reductions in cardiorespiratory fitness experienced by many cancer patients following exposure to anthracyclines¹. This work found anthracycline-containing treatments reduced average $VO_{2\text{ peak}}$ levels in cancer patients by 11% (equivalent to 11 years of normal ageing), with the rates of functional disability nearly doubling. In the same cancer patient population, currently used metrics of chemotherapy-induced cardiac damage (e.g. reductions in left ventricular ejection fraction or LVEF) showed no significant change (59% vs. 58%)¹.

Race Chief Executive Officer, Dr Daniel Tillett said: *“I am thrilled to welcome Erin to Race's Scientific Advisory Board. It is no overstatement to say that Erin and her collaborators' discoveries have provided Race with an incredible opportunity to accelerate our clinical program and bring our new formulation of bisantrene to patients sooner. The importance of $VO_{2\text{ peak}}$ as a clinically relevant endpoint in cardiology is well established, but its use is highly innovative in oncology. The entire team at Race is looking forward to drawing on Erin's insights and experience as we advance bisantrene through the clinic in 2024 and beyond.”*

Associate Professor Erin Howden said *“I am delighted to be joining the Scientific Advisory Board at Race Oncology. I am passionate about reducing the burden of cardiovascular disease for cancer patients and I am looking forward to sharing my expertise to help tackle this major problem in cancer survivorship.”*

1.Howden, E. J. *et al.* Traditional markers of cardiac toxicity fail to detect marked reductions in cardiorespiratory fitness among cancer patients undergoing anti-cancer treatment. *Eur. Hear. J. - Cardiovasc. Imaging* 22, 451–458 (2021).

-ENDS-

About Associate Professor Erin Howden

Associate Professor Erin Howden is Head of the Cardiometabolic Health and Exercise Physiology Lab, Co-lead of the Physical Activity Program and Co-chair of the Research Training and Education Committee at the Baker Heart and Diabetes Institute. She is an honorary Senior Research Fellow in the Department of Cardiometabolic Medicine at the University of Melbourne and the School of Public Health and Preventative Medicine at Monash University. After receiving her PhD from the University of Queensland in 2012, Erin completed four years of postdoctoral training at the Institute for Exercise and Environmental Medicine (Texas, USA). In 2020, Erin was awarded a prestigious Heart Foundation Future Leader Fellowship and was recognised by the Baker Institute as an Emerging Leader through the award of the Sir Laurence Muir Prize.

Associate Professor Howden is Co-chair of the Cardio-oncology Exercise Rehab Working Group of the International Cardio-oncology Society. Erin has received more than \$5 million in competitive grant funding and has an H-index of 28.

About the Baker Heart and Diabetes Institute

The Baker Heart and Diabetes Institute is an independent, internationally renowned medical research facility, with a history spanning more than 97 years. The Institute's work extends from the laboratory to wide-scale community studies with a focus on diagnosis, prevention and treatment of diabetes, cardiovascular disease and associated metabolic diseases.

The comprehensive range of research undertaken to target these deadly diseases, combined with the flexibility and innovation to respond to changing health and community needs, is unique and sets the Baker Institute apart from other health and research Institutes.

The Institute's mission is to reduce death and disability from cardiovascular disease, diabetes and related disorders; two prevalent and complex diseases responsible for the most deaths and the highest health costs in the world.

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anticancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.



Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au